相关实验视频

Updated: Sep 18, 2025

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

KCTD9的表达预测了免疫疗法反应,并增强了结肠腺癌中的抗PD-1疗效

Lei Wu¹, Shengnan Sun², Pengyuan Song¹

¹Department of Oncology, Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, P.R. China.

International journal of surgery (London, England)

|June 25, 2025

概括

KCTD9是一种新的生物标志物,可预测结肠腺癌 (COAD) 免疫治疗反应. 高KCTD9表达与更好的预后和PD-1抑制剂增强的抗瘤作用相关.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
生物标志物发现发现

背景情况:

结肠腺癌 (COAD) 是一种流行癌症.
针对PD-1/PD-L1的免疫疗法显示出希望,但在COAD中有效性有限.
预测性生物标志物是必要的,以确定谁将从免疫治疗中受益的患者.

研究的目的:

确定和验证一种用于预测COAD免疫疗法反应的新生物标志物.
探索KCTD9与结肠癌的预后和免疫相关的关联.

主要方法:

转录式表达式分析转录式表达式分析
细胞通路活动分析
免疫透分析
在活体老鼠异种移植模型中.
KCTD9表达式验证的验证方法

主要成果:

KCTD9的表达与改善结肠癌的预后有关.
KCTD9与微卫星不稳定性 (MSI) 和瘤突变负担 (TMB) 有积极的相关性.
高KCTD9表达增强CD8+T细胞透和PD-1抑制剂的抗瘤功效.

结论:

KCTD9是预测COAD免疫疗法疗效的有前途的生物标志物.
KCTD9表达与良好的预后和对PD-1/PD-L1治疗的增强反应有关.
进一步研究KCTD9作为预测生物标志物是有必要的.

关键词:

KCTD9KCTD9 KCTD9 KCTD9 KCTD9 KCTD9 KCTD9 KCTD9 结肠腺癌是结肠腺癌.免疫疗法免疫疗法

更多相关视频

Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry

Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry

Published on: October 9, 2018

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.